Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

Squamous Cell Carcinoma Clinical Trial

Official title:

A Phase 2 Open Label, Single Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel as Neoadjuvant Therapy in Patients Undergoing Surgical Resection of Squamous Cell Carcinoma (SCC)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03875859
• Other study ID #: IRB-49542
• Secondary ID: SKIN0050
• Status: Terminated
• Phase: Phase 2
• Start date: December 12, 2019
• Est. completion date: January 30, 2021

Study information

• Verified date: April 2021
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.

Description:

The primary purpose of this study is: - to determine if 8 weeks of topical remetinostat gel applied 3 times daily (TID) under occlusion will suppress SCC growth - to determine the overall response rate (ORR) of SCCs after 8 weeks of treatment with topical remetinostat gel 1%, as measured by at least 30% decrease in greatest area (in mm2). - Subjects with at least 1 biopsy-proven cutaneous SCC will be recruited for this study. - Subjects will apply remetinostat gel 1% to at least 1 SCC. - Non-invasive cutaneous SCC lesions, including Bowen's disease, are also eligible for this study - There is 1 treatment option: Topical remetinostat gel 1% applied 3 times daily. - The study is a single arm, open label design - For purposes of ClinicalTrials.gov, there is no secondary outcome.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: January 30, 2021
• Est. primary completion date: May 14, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Must have at least one biopsy-proven cutaneous SCC or SCC in situ (SCC-IS) lesion greater than or equal to 5 mm. Non-invasive SCC lesion(s), including Bowen's disease (SCC-IS), are eligible, but must be amenable to surgical resection.

2. 18 years of age or older.

3. Must be willing to apply the topical remetinostat 3 times daily for 8 weeks and cover with an occlusive bandage.

4. Negative serum pregnancy test within 14 days prior to the first dose of study therapy for women of child-bearing potential, defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months)

5. Sexually active women of child bearing potential (WCBP) and male patients with a female partner of child-bearing potential must agree to use acceptable methods of contraception to avoid pregnancy (for example, oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) before the first dose of study therapy and for 3 months after the last dose of study therapy

6. Has signed and dated the current, approved informed consent document.

Exclusion Criteria:

1. Any large (> 20 mm) SCC lesion. Patients with large SCC lesion(s) will be referred for evaluation for surgical resection.

2. Inoperable locally-advanced and/or non-cutaneous metastatic SCC.

3. SCC lesion(s) in cosmetically-sensitive areas (e.g. tip of nose, eyelid) are not eligible for enrollment. (If a patient has SCC lesion(s) in other areas, those tumor(s) may be considered for enrollment.)

4. Taking any medication known to affect SCC growth

5. Within the past 6 months, has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study. Specifically, these

include the topical use at the site of the study tumors:

• Glucocorticoids
• Retinoids either systemically or topically at the tumor site (e.g., etretinate, isotretinoin, tazarotene, tretinoin, adapalene)
• Alpha-hydroxy acids (e.g., glycolic acid, lactic acid) to the tumor site
• 5-fluorouracil or imiquimod

6. Has received treatment with systemic chemotherapy within 60 days prior to starting study medication.

7. Currently receiving systemic medications that could affect SCC tumors (e.g., oral retinoids) or might interact with remetinostat

8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recurrent seizure history or psychiatric illness/social situations that would limit compliance with study requirements.

9. Moderate to significant immunosuppression (e.g., active cancer, significant autoimmune disease) and/or receiving immunosuppressive drugs that result in moderate to significant immunosuppression (e.g. low dose oral glucocorticoids do not necessarily exclude a patient)

10. Known or previous hypersensitivity to HDACi

11. History of congestive heart failure, cardiac arrhythmias, or other findings of ventricular dysfunction.

12. Pregnancy or breast-feeding.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Squamous Cell Carcinoma

Intervention

Drug:
• Remetinostat
Topical 1% remetinostat gel

Locations

Country	Name	City	State
United States	Stanford Medical Center	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Kavita Sarin	Medivir

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response (OR)	Overall response (OR) will be assessed in squamous cell carcinoma (SCC). Objective response (OR) will defined as the number of lesions with either a complete response (CR) or a partial response (PR) among all eligible and treated lesions, any time within 10 weeks.; Complete Response (CR) = Disappearance of target lesion; Partial Response (PR) = = 30% decrease in the sum of the longest diameter of target lesion; Overall Response (OR) = CR + PR	10 weeks
Secondary	Adverse Events Contributing to Treatment Discontinuation or Interruption	Adverse events (AEs) contributing to treatment discontinuation or interruption are reported as the number of such events, a number without dispersion.	8 weeks
Secondary	Participants Who Discontinued Treatment or Had Treatment Interruption	The number of participants who discontinued treatment or experienced treatment interruption within the first 8 weeks of treatment are reported as the number of such participants, a number without dispersion.	8 weeks